Plasma and Saliva Irisin Levels of Patients with Diabetic Nephropathy and Non-Diabetic Proteinuria

被引:1
|
作者
Gurel, Ali [1 ]
Atli, Hasan [2 ]
Duzenci, Deccane [2 ]
Aydin, Suleyman [3 ]
Dogukan, Ayhan [2 ]
机构
[1] Mengucek Gazi Educ & Res Hosp, Dept Nephrol, Erzincan, Turkey
[2] Firat Univ, Fac Med, Dept Internal Med, TR-23169 Elazig, Turkey
[3] Firat Univ, Fac Med, Dept Med Biochem, TR-23169 Elazig, Turkey
关键词
Proteinuria; Diabetic nephropathy; Irisin;
D O I
10.5262/tndt.2015.1003.09
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Primary glomerular diseases or some systemic disorders such as diabetes (DM) may cause proteinuria. Irisin (IRI) is a hormone secreted as a response to physical exercise by the skeleton muscle and thought to be protective against many metabolic disorders such as DM, obesity. Decreased levels of irisin were observed in chronic kidney disease (CKD), type 2 DM and obesity. The aim of this study was to determine IRI levels in blood and saliva of proteinuric patients with and without diabetes. MATERIAL and METHODS: Sampling was from 15 diabetic, 15 non-diabetic proteinuria and 13 healthy control subjects. IRI concentrations were measured by using commercial ELISA kits. Statistical analysis was performed using SPSS 12. Groups were compared by the Kruskal-Wallis test and then Mann-Whitney post hoc test was performed. RESULTS: Plasma and saliva IRI levels of non-diabetic group were higher than the diabetic group. There was a significant positive correlation between plasma IRI concentrations and HDL, albumin levels but a negative correlation between plasma IRI and LDL levels. CONCLUSION: IRI levels were low both in plasma and saliva in diabetic subjects. IRI may be an important marker and/or therapeutic agent for disorders associated with energy expenditure and kidney diseases in the future.
引用
收藏
页码:302 / 306
页数:5
相关论文
共 50 条
  • [21] Plasma resistin, leptin and adiponectin levels in non-diabetic and diabetic obese subjects
    Silha, JV
    Krsek, M
    Skrha, J
    Sucharda, P
    Nyomba, BLG
    Murphy, LJ
    DIABETIC MEDICINE, 2004, 21 (05) : 497 - 499
  • [22] Malondialdehyde, an indicator of lipid peroxidation, concentrations in patients with diabetic nephropathy and non-diabetic nephropathy undergoing hemodialysis
    Avci, E.
    Cevher, S. C.
    Cakir, E.
    Yaman, H.
    Bilgi, C.
    FEBS JOURNAL, 2011, 278 : 390 - 390
  • [23] THE PROTEINURIA OF DIABETIC NEPHROPATHY
    JONES, RH
    MARSHALL, WJ
    MYERS, RC
    WATKINS, PJ
    PARSONS, V
    CLINICA CHIMICA ACTA, 1980, 108 (03) : 375 - 383
  • [24] COMPOSITION OF THE PLASMA, AQUEOUS AND LENS OF DIABETIC AND NON-DIABETIC CATARACT PATIENTS
    LUCAS, VA
    DUNCAN, G
    DAVIES, PD
    OPHTHALMIC RESEARCH, 1984, 16 (04) : 210 - 210
  • [25] Plasma lipoproteins and severity of coronary atherosclerosis in diabetic and non-diabetic patients
    Ferrières, J
    Elbaz, M
    Piot, C
    Carrié, D
    Galinier, M
    Fauvel, JM
    Cambou, JP
    Puel, J
    EUROPEAN HEART JOURNAL, 2003, 24 : 122 - 122
  • [26] Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy
    Friedman, AN
    Hunsicker, LG
    Selhub, J
    Bostom, AG
    DIABETES CARE, 2002, 25 (11) : 2037 - 2041
  • [27] DIABETIC (DGS) AND NON-DIABETIC NEPHROPATHY IN PATIENTS (PTS) WITH DIABETES-MELLITUS (DM)
    GLICKMAN, JL
    STURGILL, BC
    BOLTON, WK
    KIDNEY INTERNATIONAL, 1985, 27 (01) : 138 - 138
  • [28] Predictive factors for non-diabetic nephropathy in diabetic patients. The utility of renal biopsy
    Bermejo, Sheila
    Jose Soler, Maria
    Gimeno, Javier
    Barrios, Clara
    Rodriguez, Eva
    Mojal, Sergi
    Pascual, Julio
    NEFROLOGIA, 2016, 36 (05): : 535 - 544
  • [29] Blood levels of total homocysteine in patients with type 1 diabetes (with no complications, diabetic nephropathy and/or retinopathy) and in their non-diabetic relatives
    Matteucci, E
    Rossi, L
    Mariani, S
    Fagnani, F
    Quilici, S
    Cinapri, V
    Giampietro, O
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2002, 12 (04) : 184 - 189
  • [30] Effectiveness and safety of finerenone in non-diabetic patients with IgA nephropathy
    Tang, Chen
    Si, Feng-Lei
    Chen, Pei
    Hou, Wan-Yin
    Yang, Hong-Yu
    Lv, Ji-Cheng
    Shi, Su-Fang
    Zhou, Xu-Jie
    Liu, Li-Jun
    Zhang, Hong
    JOURNAL OF NEPHROLOGY, 2025,